硬纤维瘤治疗策略的变化及新进展

李舒 方志伟

李舒, 方志伟. 硬纤维瘤治疗策略的变化及新进展[J]. 中国肿瘤临床, 2023, 50(3): 130-134. doi: 10.12354/j.issn.1000-8179.2023.20220949
引用本文: 李舒, 方志伟. 硬纤维瘤治疗策略的变化及新进展[J]. 中国肿瘤临床, 2023, 50(3): 130-134. doi: 10.12354/j.issn.1000-8179.2023.20220949
Shu Li, Zhiwei Fang. Changes and development in the management of desmoid tumors[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 50(3): 130-134. doi: 10.12354/j.issn.1000-8179.2023.20220949
Citation: Shu Li, Zhiwei Fang. Changes and development in the management of desmoid tumors[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 50(3): 130-134. doi: 10.12354/j.issn.1000-8179.2023.20220949

硬纤维瘤治疗策略的变化及新进展

doi: 10.12354/j.issn.1000-8179.2023.20220949
基金项目: 本文课题受吴阶平医学基金会临床科研专项资助基金(编号:320.6750.18471)和希思科-石药肿瘤研究基金项目(编号:Y-sy2018-152)资助
详细信息
    作者简介:

    李舒:专业方向为骨与软组织肿瘤的外科与药物治疗

    通讯作者:

    方志伟 fzhiwei66@163.com

Changes and development in the management of desmoid tumors

Funds: The work was supported by the Wu Jieping Medical Foundation Clinical Research Fund (No. 320.6750.18471) and the CSCO-CSPC Oncology Research Fund (No. Y-sy2018-152)
More Information
  • 摘要: 硬纤维瘤是一种罕见的中间性肿瘤,可侵袭性生长、罕见恶变、不会转移。对于该病,传统的治疗理念是手术切除。但近年来,该病的治疗理念发生了巨大变化,治疗策略越来越趋向于保守,不仅体现在药物治疗地位的提高,手术、放疗地位的下降,更体现在密切监测作为一线治疗策略取代了以往确诊即治疗的理念。新的药物及新的治疗方法逐渐涌现,为硬纤维瘤患者提供了更多的治疗选择。

     

  • 图  1  硬纤维瘤协作组:硬纤维瘤治疗路径[5]

    ILP:隔离肢体灌注

  • [1] Kasper B, Ströbel P, Hohenberger P. Desmoid tumors: clinical features and treatment options for advanced disease[J]. Oncologist, 2011, 16:682-693. doi: 10.1634/theoncologist.2010-0281
    [2] Tsukamoto S, Takahama T, Mavrogenis AF, et al. Clinical outcomes of medical treatments for progressive desmoid tumors following active surveillance: a systematic review[J]. Musculoskelet Surg, 2022.[Epub ahead of print]
    [3] Gounder MM, Mahoney MR, van Tine BA, et al. Sorafenib for advanced and refractory desmoid tumors[J]. N Engl J Med, 2018, 379(25):2417-2428. doi: 10.1056/NEJMoa1805052
    [4] Schut AW, Timbergen MJM, van Broekhoven DLM, et al. A nationwide prospective clinical trial on active surveillance in patients with non-intra-abdominal desmoid-type fibromatosis: the GRAFITI trial[J]. Ann Surg, 2022.[Epub ahead of print]
    [5] Desmoid Tumor Working Group. The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients[J]. Eur J Cancer, 2020, 127:96-107. doi: 10.1016/j.ejca.2019.11.013
    [6] Zanchetta E, Ciniselli CM, Bardelli A, et al. Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid-type fibromatosis[J]. Cancer Med, 2021, 10(13):4356-4365. doi: 10.1002/cam4.3973
    [7] Murase F, Nishida Y, Hamada S, et al. Trends in diagnostic and therapeutic strategies for extra-abdominal desmoid-type fibromatosis: Japanese musculoskeletal oncology group questionnaire survey[J]. Jpn J Clin Oncol, 2021, 51(11):1615-1621. doi: 10.1093/jjco/hyab146
    [8] Sobczuk P, Agnieszczak IM, Grycuk W, et al. What is the best front-line approach in patients with desmoid fibromatosis? A retrospective analysis from a reference center[J]. Eur J Surg Oncol, 2021, 47(10):2602-2608. doi: 10.1016/j.ejso.2021.05.002
    [9] Cuomo P, Scoccianti G, Schiavo A, et al. Extra-abdominal desmoid tumor fibromatosis: a multicenter EMSOS study[J]. BMC Cancer, 2021, 21(1):437. doi: 10.1186/s12885-021-08189-6
    [10] Tsukamoto S, Tanzi P, Mavrogenis AF, et al. Upfront surgery is not advantageous compared to more conservative treatments such as observation or medical treatment for patients with desmoid tumors[J]. BMC Musculoskelet Disord, 2021, 22(1):12. doi: 10.1186/s12891-020-03897-9
    [11] Salas S, Dufresne A, Bui B, et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation[J]. J Clin Oncol, 2011, 29(26):3553-3558. doi: 10.1200/JCO.2010.33.5489
    [12] Gluck I, Griffith KA, Biermann JS, et al. Role of radiotherapy in the management of desmoid tumors[J]. Int J Radiat Oncol Biol Phys, 2011, 80(3):787-792. doi: 10.1016/j.ijrobp.2010.02.053
    [13] Pignatti G, Barbanti-Bròdano G, Ferrari D, et al. Extraabdominal desmoid tumor. A study of 83 cases[J]. Clin Orthop Relat Res, 2000(375):207-213.
    [14] Shin SH, Ko KR, Cho SK, et al. Surgical outcome of desmoid tumors: adjuvant radiotherapy delayed the recurrence, but did not affect long-term outcomes[J]. J Surg Oncol, 2013, 108(1):28-33. doi: 10.1002/jso.23343
    [15] Rutenberg MS, Indelicato DJ, Knapik JA, et al. External-beam radiotherapy for pediatric and young adult desmoid tumors[J]. Pediatr Blood Cancer, 2011, 57(3):435-442. doi: 10.1002/pbc.22916
    [16] Chugh R, Wathen JK, Patel SR, et al. Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial[J]. Clin Cancer Res, 2010, 16(19):4884-4891. doi: 10.1158/1078-0432.CCR-10-1177
    [17] Penel N, Le Cesne A, Bui BN, et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up[J]. Ann Oncol, 2011, 22(2):452-457. doi: 10.1093/annonc/mdq341
    [18] 李舒,樊征夫,刘佳勇,等.不可手术切除韧带样型纤维瘤伊马替尼治疗疗效分析[J].中华肿瘤防治杂志,2018,25(8):591-594. doi: 10.16073/j.cnki.cjcpt.2018.08.013
    [19] Gounder MM, Lefkowitz RA, Keohan ML, et al. Activity of sorafenib against desmoid tumor/deep fibromatosis[J]. Clin Cancer Res, 2011, 17(12):4082-4090. doi: 10.1158/1078-0432.CCR-10-3322
    [20] Toulmonde M, Pulido M, Ray-Coquard I, et al. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study[J]. Lancet Oncol, 2019, 20(9):1263-1272. doi: 10.1016/S1470-2045(19)30276-1
    [21] Li S, Fan Z, Fang Z, et al. Efficacy of vinorelbine combined with low-dose methotrexate for treatment of inoperable desmoid tumor and prognostic factor analysis[J]. Chin J Cancer Res, 2017, 29(5):455-462. doi: 10.21147/j.issn.1000-9604.2017.05.10
    [22] Garbay D, Le Cesne A, Penel N, et al. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG)[J]. Ann Oncol, 2012, 23(1):182-186. doi: 10.1093/annonc/mdr051
    [23] Constantinidou A, Jones RL, Scurr M, et al. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis[J]. Eur J Cancer, 2009, 45(17):2930-2934. doi: 10.1016/j.ejca.2009.08.016
    [24] 李舒,方志伟,刘佳勇,等.多柔比星脂质体联合达卡巴嗪治疗不可手术切除硬纤维瘤的疗效初探[J].中国肿瘤临床,2021,48(14):716-720.
    [25] Villalobos VM, Hall F, Jimeno A, et al. Long-term follow-up of desmoid fibromatosis treated with PF-03084014, an oral Gamma secretase inhibitor[J]. Ann Surg Oncol, 2018, 25(3):768-775. doi: 10.1245/s10434-017-6082-1
    [26] Kummar S, O'Sullivan Coyne G, Do KT, et al. Clinical activity of the γ-secretase inhibitor PF-03084014 in adults with desmoid tumors (aggressive fibromatosis)[J]. J Clin Oncol, 2017, 35(14):1561-1569. doi: 10.1200/JCO.2016.71.1994
    [27] Zhu HC, Xu SX, Li XT, et al. MRI T1 contrast-enhanced signal intensity is a prognostic indicator of imatinib therapy in desmoid-type fibromatosis[J]. Front Oncol, 2021, 11: 615986.
    [28] Zhang R, Chen JY, Zhang L, et al. The safety and ablation efficacy of ultrasound-guided high-intensity focused ultrasound ablation for desmoid tumors[J]. Int J Hyperthermia, 2021, 38(2):89-95. doi: 10.1080/02656736.2021.1894359
    [29] Mandel JE, Kim D, Yarmohammadi H, et al. Percutaneous cryoablation provides disease control for extra-abdominal desmoid-type fibromatosis comparable with surgical resection[J]. Ann Surg Oncol, 2022, 29(1):640-648. doi: 10.1245/s10434-021-10463-7
    [30] Martínez-Martínez A, García-Espinosa J, Láinez Ramos-Bossini AJ, et al. Percutaneous microwave ablation of desmoid fibromatosis[J]. Korean J Radiol, 2021, 22(6):944-950. doi: 10.3348/kjr.2020.0768
  • 加载中
图(1)
计量
  • 文章访问数:  1689
  • HTML全文浏览量:  238
  • PDF下载量:  259
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-06-22
  • 录用日期:  2022-09-15
  • 修回日期:  2022-09-10
  • 网络出版日期:  2022-10-18

目录

    /

    返回文章
    返回